Antiemetic Efficacy of Aprepitant in Cisplatin–Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study
Anticancer Research · 2026
DOI: 10.21873/anticanres.18207 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Anticancer Research, 2026. Verfasst von Kengo Umehara und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, NHO Hokkaido Cancer Center, Sapporo, Japan. Hauptthemen laut MEDLINE: Antiemetics, Aprepitant, Biliary Tract Neoplasms, Cisplatin.
Abstract (Originalsprache)
BACKGROUND/AIM: Chemotherapy-induced nausea and vomiting (CINV) is a significant issue among the adverse events associated with chemotherapy, and the management of nausea remains inadequate. Although international guidelines classify gemcitabine plus cisplatin (GC) therapy as having a high emetogenic risk, Japanese guidelines categorize it as moderate risk. This study aimed to evaluate the effects of aprepitant as a prophylactic antiemetic in conjunction with GC therapy for biliary tract cancer in a real-world setting. PATIENTS AND METHODS: This retrospective study was conducted at 12 hospitals in Japan. Patients who received their first cycle of GC therapy between January 2012 and June 2023 were included. Propensity-score matching was used to adjust for differences in the baseline patient characteristics. The primary endpoint was the total control (TC) rate in the delayed phase, which was defined as 24-120 h post chemotherapy. RESULTS: After propensity-score matching, 129 patients were included in each group. The TC rates in the delayed phase and overall (0-168 h) were significantly higher in the aprepitant group than in the non-aprepitant group (90.7% vs. 71.3%, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, NHO Hokkaido Cancer Center, Sapporo, Japan.
- Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan; saito-yo@hus.ac.jp.
- Alpha Pharmacy, Sapporo, Japan.
- Department of Pharmacy, Teine Keijinkai Hospital, Sapporo, Japan.
- Department of Pharmacy, Hokkaido Gastroenterology Hospital, Sapporo, Japan.
- Department of Pharmacy, Tonan Hospital, Sapporo, Japan.
Zitieren
APA
Umehara, K., Saito, Y., Hirate, D., Kooka, A., Fujibayashi, R., Takasaki, S., Shimoguchiya, T., Kusakabe, A., Hatakeyama, T., Hasegawa, Y., Shimizu, A., Ota, A., Maeda, K., Watanabe, T., Takada, S., Obara, T., Nagashima, H., Sagawa, T., Fujikawa, K., & Kawaguchi, H. (2026). Antiemetic Efficacy of Aprepitant in Cisplatin–Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study. Anticancer Research. https://doi.org/10.21873/anticanres.18207
Vancouver
Umehara K, Saito Y, Hirate D, Kooka A, Fujibayashi R, Takasaki S, et al. Antiemetic Efficacy of Aprepitant in Cisplatin–Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study. Anticancer Research. 2026. doi:10.21873/anticanres.18207
BibTeX
@article{Umehara2026,
author = {Umehara, Kengo and Saito, Yoshitaka and Hirate, Daisuke and Kooka, Aya and Fujibayashi, Ryo and Takasaki, Shuichi and Shimoguchiya, Takashi and Kusakabe, Ayuko and Hatakeyama, Tomoaki and Hasegawa, Yuki and Shimizu, Atsuya and Ota, Akihide and Maeda, Kenta and Watanabe, Taiki and Takada, Shinya and Obara, Takako and Nagashima, Hiroyuki and Sagawa, Tamotsu and Fujikawa, Koshi and Kawaguchi, Hiroyuki},
title = {Antiemetic Efficacy of Aprepitant in Cisplatin–Gemcitabine Therapy for Biliary Tract Cancer: A Multicenter Study},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18207}
}
EUVIMED